Abstract: Objective To evaluate the efficacy and toxicity of modified DCF regimen compared with FOLFOX 4 regimen as the first-line treatment for patients with advanced gastric cancer. Methods Form January 2010 to July 2013， 47 advanced gastric carcinoma patients were enrolled in this study. Twenty-four patients received modified DCF regimen（docetaxel 60mg／m2iv，d1； oxaliplatin 100mg／m2 iv, d1； fluorouracil 400 mg／m2 iv, d1-d2； fluorouracil 600 mg／m2civ 48h， d2-d3； 21 days was a cycle） and 23 patients received FOLFOX 4 regimen（oxaliplatin 85mg／m2 iv，d1； calcium folinate 200mg／m2 iv， d1-d2； fluorouracil 400mg／m2iv， d1-d2； fluorouracil 600 mg／m2 civ 22h； 14 days was a cycle）. The efficacy was evaluated every 6 weeks. The response rate（RR）， disease control rate（DCR）， progression-free survival（PFS）and overall survival（OS）were analyzed between the two groups. Results Efficacy could be evaluated in all patients. Patients in modified DCF group achieved PR in 6 cases， SD in 16 cases and PD in 2 cases with RR of 25.0％ and DCR of 91.6％. Patients in FOLFOX 4 group achieved PR in 2 cases， SD in 16 cases and PD in 5 cases with RR of 8.6％ and DCR of 78.2％. The differences of DCR and RR between the two groups had no significance（P＞0.05）. Meanwhile， the median PFS and OS were 8.2 and 11.5 months in modified DCF group and 5.8 and 10.1 months in FOLFOX 4 group with no significant differences（P＞0.05）. The main toxicities were myelosuppression and digestive tract reaction， mainly in grade 1-2， and the incidence of the two groups had no differences（P＞0.05）. Conclusion There are similar efficacy and toxicities between modified DCF regimen and FOLFOX 4 regimen， which is worth further study.